Accessibility Menu
 
Coeptis Therapeutics logo

Coeptis Therapeutics

(NASDAQ) COEP

Current Price$14.90
Market Cap$102.06M
Since IPO (2020)-92%
5 Year-92%
1 Year+97%
1 Month+42%

Coeptis Therapeutics Financials at a Glance

Market Cap

$102.06M

Revenue (TTM)

$1.36M

Net Income (TTM)

$8.33M

EPS (TTM)

$-2.80

P/E Ratio

-5.86

Dividend

$0.00

Beta (Volatility)

0.47 (Low)

Price

$14.90

Volume

5,698

Open

$18.00

Previous Close

$14.90

Daily Range

$10.29 - $18.00

52-Week Range

$6.80 - $21.41

COEP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Coeptis Therapeutics

Industry

Biotechnology

Employees

6

CEO

David Mehalick

Headquarters

Wexford, PA 15090, US

COEP Financials

Key Financial Metrics (TTM)

Gross Margin

-2%

Operating Margin

-10%

Net Income Margin

-6%

Return on Equity

-97%

Return on Capital

-72%

Return on Assets

-42%

Earnings Yield

-17.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$102.06M

Shares Outstanding

6.22M

Volume

5.70K

Short Interest

0.00%

Avg. Volume

53.23K

Financials (TTM)

Gross Profit

$2.83M

Operating Income

$13.04M

EBITDA

$11.82M

Operating Cash Flow

$8.60M

Capital Expenditure

$0.00

Free Cash Flow

$8.60M

Cash & ST Invst.

$6.35M

Total Debt

$268.88K

Coeptis Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$862.05K

N/A

Gross Profit

$3.20M

-1130.1%

Gross Margin

-3.71%

N/A

Market Cap

$102.06M

N/A

Market Cap/Employee

$20.41M

N/A

Employees

5

N/A

Net Income

$1.58M

+47.6%

EBITDA

$2.29M

+14.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$6.08M

+802.2%

Accounts Receivable

$7.35K

N/A

Inventory

$0.00

N/A

Long Term Debt

$150.00K

-11.2%

Short Term Debt

$118.88K

-90.3%

Return on Assets

-41.98%

N/A

Return on Invested Capital

-72.17%

N/A

Free Cash Flow

$1.69M

-17.5%

Operating Cash Flow

$1.69M

-17.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OSTXOS Therapies Incorporated
$1.77+0.00%
KPTIKaryopharm Therapeutics Inc.
$8.66+0.00%
EQEquillium, Inc.
$2.04-5.56%
NRXPNRx Pharmaceuticals, Inc.
$3.03+3.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
POETPoet Technologies
$7.95-0.47%
NOKNokia
$10.76+0.03%
OGNOrganon & Co.
$13.16+0.17%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.32+0.01%

Questions About COEP

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.